About this episode
In this week's Daybreak Special episode, hosts Snigdha Sharma and Rahel Philipose speak to The Ken's Shivani Verma about her investigation into Pharmeasy's dubious business practices.
The once IPO-bound company is under the scanner for its 'unethical' ways of upselling alternative medicines and supplements. Everyone – from Pharmeasy's own pharmacists, to the doctors who call behalf of the company to validate a customer's prescription – are under pressure to sell these supplements.
The saga began with Pharmeasy’s 2021 acquisition of Bengaluru-based e-pharmacy Medlife, where former executives noted a similar trend of upselling alternatives and supplements. This comes amid ballooning losses and immense pressure from investors to show profitability.
So what's the deal? Why is Pharmeasy going down this route?
Tune in to find out.
Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.
P.S. Daybreak episodes drop daily now :)
Get every episode summarized
Each time Daybreak publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Daybreak
This week in AI: activist robots, doom-laden researchers — so who's the good guy...
Daybreak
India has more tourists than ever. So why is tourism in trouble?
Daybreak
The Government sold Air India to escape its problems. The fix is to buy back in
Daybreak
Nykaa cracked fashion at last. Myntra sees no reason to panic
Daybreak